Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 38945 | 8 |
09:34 ET | 1173 | 8.12 |
09:36 ET | 2457 | 8.1 |
09:38 ET | 2657 | 8.04 |
09:39 ET | 4647 | 8.105 |
09:41 ET | 4823 | 8.115 |
09:43 ET | 10294 | 8.09 |
09:45 ET | 3530 | 8.13 |
09:48 ET | 300 | 8.05 |
09:50 ET | 2673 | 8.02 |
09:52 ET | 830 | 8.02 |
09:54 ET | 12085 | 8.09 |
09:56 ET | 8548 | 8.07 |
09:57 ET | 3460 | 8.1 |
09:59 ET | 2417 | 8.07 |
10:01 ET | 4638 | 8.11 |
10:03 ET | 12458 | 8.13 |
10:06 ET | 2100 | 8.11 |
10:08 ET | 5574 | 8.135 |
10:10 ET | 6386 | 8.165 |
10:12 ET | 4202 | 8.13 |
10:14 ET | 1300 | 8.1 |
10:15 ET | 2352 | 8.1 |
10:17 ET | 4550 | 8.1 |
10:19 ET | 800 | 8.1 |
10:21 ET | 10879 | 8.03 |
10:24 ET | 2365 | 8.05 |
10:26 ET | 800 | 8.04 |
10:28 ET | 1438 | 8.04 |
10:30 ET | 1357 | 8.06 |
10:32 ET | 5898 | 8.09 |
10:33 ET | 999 | 8.08 |
10:35 ET | 5215 | 8.1 |
10:37 ET | 1966 | 8.13 |
10:39 ET | 5213 | 8.13 |
10:42 ET | 300 | 8.145 |
10:44 ET | 2900 | 8.14 |
10:46 ET | 4271 | 8.13 |
10:48 ET | 2449 | 8.135 |
10:50 ET | 1610 | 8.135 |
10:51 ET | 8857 | 8.15 |
10:53 ET | 3203 | 8.12 |
10:55 ET | 12665 | 8.09 |
10:57 ET | 3563 | 8.13 |
11:00 ET | 1600 | 8.13 |
11:02 ET | 1764 | 8.12 |
11:04 ET | 2100 | 8.12 |
11:06 ET | 8526 | 8.1 |
11:08 ET | 1145 | 8.1 |
11:09 ET | 6061 | 8.1 |
11:11 ET | 8539 | 8.11 |
11:13 ET | 11590 | 8.1 |
11:15 ET | 13559 | 8.09 |
11:18 ET | 7726 | 8.05 |
11:20 ET | 28223 | 8.01 |
11:22 ET | 3901 | 8.01 |
11:24 ET | 1162 | 8.01 |
11:26 ET | 1970 | 8.01 |
11:27 ET | 4123 | 8.03 |
11:29 ET | 3529 | 8.02 |
11:31 ET | 3892 | 8.04 |
11:33 ET | 27393 | 7.98 |
11:36 ET | 21542 | 7.99 |
11:38 ET | 12653 | 7.99 |
11:40 ET | 1600 | 7.99 |
11:42 ET | 1615 | 7.99 |
11:44 ET | 27202 | 7.96 |
11:45 ET | 2572 | 7.97 |
11:47 ET | 26929 | 7.925 |
11:49 ET | 5484 | 7.925 |
11:51 ET | 8757 | 7.93 |
11:54 ET | 2400 | 7.925 |
11:56 ET | 12436 | 7.92 |
11:58 ET | 2273 | 7.915 |
12:00 ET | 26998 | 7.905 |
12:02 ET | 54306 | 7.88 |
12:03 ET | 5080 | 7.86 |
12:05 ET | 17385 | 7.88 |
12:07 ET | 5446 | 7.9 |
12:09 ET | 2137 | 7.895 |
12:12 ET | 29407 | 7.8699 |
12:14 ET | 5030 | 7.85 |
12:16 ET | 8869 | 7.85 |
12:18 ET | 6652 | 7.85 |
12:20 ET | 2108 | 7.855 |
12:21 ET | 395 | 7.855 |
12:23 ET | 5413 | 7.855 |
12:25 ET | 2327 | 7.86 |
12:27 ET | 13965 | 7.84 |
12:30 ET | 7669 | 7.83 |
12:32 ET | 9266 | 7.84 |
12:34 ET | 21798 | 7.845 |
12:36 ET | 9567 | 7.845 |
12:38 ET | 29133 | 7.8 |
12:39 ET | 24734 | 7.785 |
12:41 ET | 60066 | 7.77 |
12:43 ET | 13635 | 7.775 |
12:45 ET | 4052 | 7.76 |
12:48 ET | 11829 | 7.775 |
12:50 ET | 1909 | 7.77 |
12:52 ET | 2420 | 7.76 |
12:54 ET | 14263 | 7.7801 |
12:56 ET | 5700 | 7.77 |
12:57 ET | 2796 | 7.76 |
12:59 ET | 11318 | 7.725 |
01:01 ET | 7587 | 7.72 |
01:03 ET | 19679 | 7.7176 |
01:06 ET | 21835 | 7.73 |
01:08 ET | 9098 | 7.73 |
01:10 ET | 9878 | 7.74 |
01:12 ET | 1350 | 7.73 |
01:14 ET | 1081 | 7.73 |
01:15 ET | 6513 | 7.73 |
01:17 ET | 15576 | 7.74 |
01:19 ET | 3535 | 7.7338 |
01:21 ET | 55707 | 7.695 |
01:24 ET | 15685 | 7.705 |
01:26 ET | 2234 | 7.695 |
01:28 ET | 7752 | 7.68 |
01:30 ET | 21222 | 7.67 |
01:32 ET | 3111 | 7.685 |
01:33 ET | 2257 | 7.685 |
01:35 ET | 52118 | 7.655 |
01:37 ET | 14335 | 7.635 |
01:39 ET | 11958 | 7.655 |
01:42 ET | 9241 | 7.645 |
01:44 ET | 1297 | 7.645 |
01:46 ET | 4386 | 7.63 |
01:48 ET | 24263 | 7.6797 |
01:50 ET | 1311 | 7.68 |
01:51 ET | 3749 | 7.67 |
01:53 ET | 600 | 7.66 |
01:55 ET | 3445 | 7.66 |
01:57 ET | 2194 | 7.665 |
02:00 ET | 10888 | 7.6798 |
02:02 ET | 1702 | 7.685 |
02:04 ET | 7536 | 7.695 |
02:06 ET | 7445 | 7.67 |
02:08 ET | 1673 | 7.6608 |
02:09 ET | 311 | 7.66 |
02:11 ET | 3448 | 7.645 |
02:13 ET | 13684 | 7.635 |
02:15 ET | 3770 | 7.63 |
02:18 ET | 14485 | 7.665 |
02:20 ET | 2780 | 7.65 |
02:22 ET | 1781 | 7.655 |
02:24 ET | 350 | 7.6503 |
02:26 ET | 1743 | 7.655 |
02:27 ET | 4029 | 7.655 |
02:29 ET | 11078 | 7.665 |
02:31 ET | 10387 | 7.665 |
02:33 ET | 2700 | 7.665 |
02:36 ET | 1823 | 7.67 |
02:38 ET | 5719 | 7.675 |
02:40 ET | 1839 | 7.685 |
02:42 ET | 3204 | 7.69 |
02:44 ET | 13055 | 7.7093 |
02:45 ET | 3539 | 7.69 |
02:47 ET | 500 | 7.695 |
02:49 ET | 3441 | 7.68 |
02:51 ET | 11336 | 7.68 |
02:54 ET | 6963 | 7.67 |
02:56 ET | 76589 | 7.64 |
02:58 ET | 9671 | 7.645 |
03:00 ET | 7345 | 7.66 |
03:02 ET | 2656 | 7.665 |
03:03 ET | 5155 | 7.675 |
03:05 ET | 6395 | 7.67 |
03:07 ET | 200 | 7.68 |
03:09 ET | 8346 | 7.66 |
03:12 ET | 7570 | 7.65 |
03:14 ET | 83379 | 7.59 |
03:16 ET | 7285 | 7.625 |
03:18 ET | 7004 | 7.65 |
03:20 ET | 10352 | 7.675 |
03:21 ET | 20882 | 7.66 |
03:23 ET | 2600 | 7.65 |
03:25 ET | 7134 | 7.66 |
03:27 ET | 7053 | 7.68 |
03:30 ET | 15315 | 7.685 |
03:32 ET | 4904 | 7.67 |
03:34 ET | 1000 | 7.66 |
03:36 ET | 10932 | 7.66 |
03:38 ET | 3883 | 7.65 |
03:39 ET | 16238 | 7.62 |
03:41 ET | 72438 | 7.59 |
03:43 ET | 20160 | 7.62 |
03:45 ET | 6478 | 7.61 |
03:48 ET | 9901 | 7.605 |
03:50 ET | 17301 | 7.585 |
03:52 ET | 44260 | 7.625 |
03:54 ET | 30051 | 7.605 |
03:56 ET | 57075 | 7.55 |
03:57 ET | 29900 | 7.56 |
03:59 ET | 328915 | 7.54 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.3B | -45.5x | --- |
Viking Therapeutics Inc | 5.7B | -55.4x | --- |
Madrigal Pharmaceuticals Inc | 5.8B | -11.8x | --- |
Krystal Biotech Inc | 5.1B | 94.4x | --- |
Nuvalent Inc | 4.7B | -30.3x | --- |
BridgeBio Pharma Inc | 4.7B | -7.7x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.3B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.97 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -45.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.